REG - Futura Medical PLC - Total Voting Rights

Futura MedicalAnnouncement

03/12/2018 13:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181203:nRSC2556Ja

RNS Number : 2556J
Futura Medical PLC
03 December 2018
 
 
Futura Medical plc
("Futura" or "the Company")
Total Voting Rights
3 December 2018
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on
advanced transdermal technology announces that, for the purposes of the FCA's
Disclosure and Transparency Rules, the Company's total issued share capital at
the date of this announcement is 204,583,439 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of
voting rights in the Company is 204,583,439 and this figure may therefore be
used by shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a change
in their interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.
 For further information please contact:                        For media enquiries please contact:
 Futura Medical plc                                             Optimum Strategic Communications
 Angela Hildreth, FD/COO                                        Mary Clark/ Hollie Vile/ Ellie Blackwell
 investor.relations@futuramedical.com                           Email: futuramedical@optimumcomms.com
 www.futuramedical.com (http://www.futuramedical.com)           Tel: +44 (0) 203 950 9144
 Tel: +44 (0) 1483 685 670
 Nominated Advisor/Broker
 N+1 Singer
 Aubrey Powell/ Ben Farrow (Corporate Finance)
 Tom Salvesen/ Mia Gardner (Corporate Broking)
 Tel: +44 (0) 20 7496 3000
 
Notes to editors:
 
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® drug delivery technology. These products are optimised for clinical
efficacy, safety, administration and patient convenience and are developed for
the prescription and consumer healthcare markets as appropriate. Current
therapeutic areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed to maximise
product differentiation and value creation whilst minimising risk.
 
Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(https://www.futuramedical.com/)
 
 
 
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.